Proteolytic processing of chemokines: Implications in physiological and pathological conditions

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 6-7, 2008, Pages 1185-1198

  Wolf, Marlene ^a   Albrecht, Stefan ^a   Märki, Christa ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cancer; Chemokine; Haematopoiesis; Inflammation; Leukocyte; Protease

Indexed keywords

CHEMOKINE; PROTEINASE;

BIOLOGICAL ACTIVITY; HEMATOPOIESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW;

ANIMALS; CHEMOKINES; HEMATOPOIESIS; HIV INFECTIONS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDE HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 43049107148     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.12.009     Document Type: Review

References (105)

1. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165 9 (2000) 5269-5277
2. Agrawal L., Vanhorn-Ali Z., and Alkhatib G. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs). J Leukoc Biol 72 5 (2002) 1063-1074
3. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 5270 (1996) 1955-1958
4. Allen S.J., Crown S.E., and Handel T.M. Chemokine: Receptor structure, interactions, and antagonism. Annu Rev Immunol 25 (2007) 787-820
5. Aquaro S., Menten P., Struyf S., Proost P., Van Damme J., De Clercq E., et al. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol 75 9 (2001) 4402-4406
6. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 250 2 (2001) 91-104
7. Baggiolini M., Dewald B., and Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 55 (1994) 97-179
8. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 4 7 (2004) 540-550
9. Berahovich R.D., Miao Z., Wang Y., Premack B., Howard M.C., and Schall T.J. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 174 11 (2005) 7341-7351
10. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta 342 1-2 (2004) 41-69
11. Burger J.A., and Kipps T.J. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107 5 (2006) 1761-1767
12. Car B.D., Baggiolini M., and Walz A. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases. Biochem J 275 Pt 3 (1991) 581-584
13. Catalfamo M., Karpova T., McNally J., Costes S.V., Lockett S.J., Bos E., et al. Human CD8+ T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity 20 2 (2004) 219-230
14. Christopherson II K.W., Hangoc G., and Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 169 12 (2002) 7000-7008
15. Comerford I., Litchfield W., Harata-Lee Y., Nibbs R.J., and McColl S.R. Regulation of chemotactic networks by 'atypical' receptors. Bioessays 29 3 (2007) 237-247
16. Conant K., McArthur J.C., Griffin D.E., Sjulson L., Wahl L.M., and Irani D.N. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 46 3 (1999) 391-398
17. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 5 (2007) 1167-1174
18. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 9 (2004) 942-949
19. Davis D.A., Singer K.E., De La Luz Sierra M., Narazaki M., Yang F., Fales H.M., et al. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 105 12 (2005) 4561-4568
20. De La Luz Sierra M., Yang F., Narazaki M., Salvucci O., Davis D., Yarchoan R., et al. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 103 7 (2004) 2452-2459
21. Delgado M.B., Clark-Lewis I., Loetscher P., Langen H., Thelen M., Baggiolini M., et al. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol 31 3 (2001) 699-707
22. Detheux M., Standker L., Vakili J., Munch J., Forssmann U., Adermann K., et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 192 10 (2000) 1501-1508
23. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 3 (2002) 161-174
24. Galvez B.G., Genis L., Matias-Roman S., Oblander S.A., Tryggvason K., Apte S.S., et al. Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J Biol Chem 280 2 (2005) 1292-1298
25. Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276 41 (2001) 37993-38001
26. Gocheva V., and Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6 1 (2007) 60-64
27. Guan E., Wang J., and Norcross M.A. Identification of human macrophage inflammatory proteins 1alpha and 1beta as a native secreted heterodimer. J Biol Chem 276 15 (2001) 12404-12409
28. Hasan L., Mazzucchelli L., Liebi M., Lis M., Hunger R.E., Tester A., et al. Function of liver activation-regulated chemokine/CC chemokine ligand 20 is differently affected by cathepsin B and cathepsin D processing. J Immunol 176 11 (2006) 6512-6522
29. Hebert C.A., Luscinskas F.W., Kiely J.M., Luis E.A., Darbonne W.C., Bennett G.L., et al. Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J Immunol 145 9 (1990) 3033-3040
30. Hensbergen P.J., Verzijl D., Balog C.I., Dijkman R., van der Schors R.C., van der Raaij-Helmer E.M., et al. Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J Biol Chem 279 14 (2004) 13402-13411
31. Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102 4 (2003) 1186-1195
32. Hundhausen C., Schulte A., Schulz B., Andrzejewski M.G., Schwarz N., von Hundelshausen P., et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 178 12 (2007) 8064-8072
33. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66 11 (2006) 5716-5722
34. Kawada K., Hosogi H., Sonoshita M., Sakashita H., Manabe T., Shimahara Y., et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26 32 (2007) 4679-4688
35. Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.J., Kuo C., et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23 12 (2005) 2744-2753
36. Kodali R., Hajjou M., Berman A.B., Bansal M.B., Zhang S., Pan J.J., et al. Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res 69 3 (2006) 706-715
37. Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35 3 (2004) 233-245
38. Kulig P., Zabel B.A., Dubin G., Allen S.J., Ohyama T., Potempa J., et al. Staphylococcus aureus-derived staphopain B, a potent cysteine protease activator of plasma chemerin. J Immunol 178 6 (2007) 3713-3720
39. Lapidot T., and Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30 9 (2002) 973-981
40. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., and Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111 2 (2003) 187-196
41. Li Q., Park P.W., Wilson C.L., and Parks W.C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111 5 (2002) 635-646
42. Lim J.K., Burns J.M., Lu W., and DeVico A.L. Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. J Leukoc Biol 78 2 (2005) 442-452
43. Lim J.K., Lu W., Hartley O., and DeVico A.L. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant. J Leukoc Biol 80 6 (2006) 1395-1404
44. Loetscher P., Moser B., and Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 74 (2000) 127-180
45. Ludwig A., and Weber C. Transmembrane chemokines: Versatile 'special agents' in vascular inflammation. Thromb Haemost 97 5 (2007) 694-703
46. Ludwig A., Schiemann F., Mentlein R., Lindner B., and Brandt E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 72 1 (2002) 183-191
47. Ma Q., Jones D., and Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10 4 (1999) 463-471
48. McQuibban G.A., Gong J.H., Tam E.M., McCulloch C.A., Clark-Lewis I., and Overall C.M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289 5482 (2000) 1202-1206
49. McQuibban G.A., Butler G.S., Gong J.H., Bendall L., Power C., Clark-Lewis I., et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 276 47 (2001) 43503-43508
50. McQuibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., and Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100 4 (2002) 1160-1167
51. Mohamed M.M., and Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6 10 (2006) 764-775
52. Moser B., Wolf M., Walz A., and Loetscher P. Chemokines: Multiple levels of leukocyte migration control. Trends Immunol 25 2 (2004) 75-84
53. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001) 50-56
54. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52 1 (2000) 145-176
55. Nakagawa H., Hatakeyama S., Ikesue A., and Miyai H. Generation of interleukin-8 by plasmin from AVLPR-interleukin-8, the human fibroblast-derived neutrophil chemotactic factor. FEBS Lett 282 2 (1991) 412-414
56. Narducci M.G., Scala E., Bresin A., Caprini E., Picchio M.C., Remotti D., et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 107 3 (2006) 1108-1115
57. Nordstrom D., Lindy O., Konttinen Y.T., Lauhio A., Sorsa T., Friman C., et al. Cathepsin G and elastase in synovial fluid and peripheral blood in reactive and rheumatoid arthritis. Clin Rheumatol 15 1 (1996) 35-41
58. Nufer O., Corbett M., and Walz A. Amino-terminal processing of chemokine ENA-78 regulates biological activity. Biochemistry 38 2 (1999) 636-642
59. Ohashi K., Naruto M., Nakaki T., and Sano E. Identification of interleukin-8 converting enzyme as cathepsin L. Biochim Biophys Acta 1649 1 (2003) 30-39
60. Ohtsuki T., Hosono O., Kobayashi H., Munakata Y., Souta A., Shioda T., et al. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV. FEBS Lett 431 2 (1998) 236-240
61. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186 11 (1997) 1865-1872
62. Overall C.M., and Kleifeld O. Tumour microenvironment-opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6 3 (2006) 227-239
63. Oynebraten I., Barois N., Hagelsteen K., Johansen F.E., Bakke O., and Haraldsen G. Characterization of a novel chemokine-containing storage granule in endothelial cells: Evidence for preferential exocytosis mediated by protein kinase A and diacylglycerol. J Immunol 175 8 (2005) 5358-5369
64. Padrines M., Wolf M., Walz A., and Baggiolini M. Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. FEBS Lett 352 2 (1994) 231-235
65. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3 7 (2002) 687-694
66. Proost P., De Meester I., Schols D., Struyf S., Lambeir A.M., Wuyts A., et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273 13 (1998) 7222-7227
67. Proost P., Struyf S., Schols D., Durinx C., Wuyts A., Lenaerts J.P., et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 432 1-2 (1998) 73-76
68. Proost P., Struyf S., Schols D., Opdenakker G., Sozzani S., Allavena P., et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 274 7 (1999) 3988-3993
69. Proost P., Menten P., Struyf S., Schutyser E., De Meester I., and Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 96 5 (2000) 1674-1680
70. Proost P., Schutyser E., Menten P., Struyf S., Wuyts A., Opdenakker G., et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98 13 (2001) 3554-3561
71. Proost P., Struyf S., and Van Damme J. Natural post-translational modifications of chemokines. Biochem Soc Trans 34 Pt 6 (2006) 997-1001
72. Proost P., Mortier A., Loos T., Vandercappellen J., Gouwy M., Ronsse I., et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 110 1 (2007) 37-44
73. Proudfoot A.E. The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 34 Pt 3 (2006) 422-426
74. Richter R., Bistrian R., Escher S., Forssmann W.G., Vakili J., Henschler R., et al. Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates mononuclear cell adhesiveness. J Immunol 175 3 (2005) 1599-1608
75. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107 1 (2001) 53-63
76. Schiemann F., Grimm T.A., Hoch J., Gross R., Lindner B., Petersen F., et al. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 107 6 (2006) 2234-2242
77. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpe S., et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 39 3 (1998) 175-187
78. Shioda T., Kato H., Ohnishi Y., Tashiro K., Ikegawa M., Nakayama E.E., et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 95 11 (1998) 6331-6336
79. Son K.N., Hwang J., Kwon B.S., and Kim J. Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun 340 2 (2006) 498-504
80. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
81. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., and Belperio J.A. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42 6 (2006) 768-778
82. Struyf S., Proost P., Sozzani S., Mantovani A., Wuyts A., De Clercq E., et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 161 6 (1998) 2672-2675
83. Struyf S., Proost P., Schols D., De Clercq E., Opdenakker G., Lenaerts J.P., et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 162 8 (1999) 4903-4909
84. Struyf S., Menten P., Lenaerts J.P., Put W., D'Haese A., De Clercq E., et al. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur J Immunol 31 7 (2001) 2170-2178
85. Struyf S., Proost P., and Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 81 (2003) 1-44
86. Tester A.M., Cox J.H., Connor A.R., Starr A.E., Dean R.A., Puente X.S., et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2 (2007) e312
87. Vakili J., Standker L., Detheux M., Vassart G., Forssmann W.G., and Parmentier M. Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active. J Immunol 167 6 (2001) 3406-3413
88. Valenzuela-Fernandez A., Planchenault T., Baleux F., Staropoli I., Le-Barillec K., Leduc D., et al. Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem 277 18 (2002) 15677-15689
89. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., and Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96 8 (2000) 2673-2681
90. Van den Steen P.E., Husson S.J., Proost P., Van Damme J., and Opdenakker G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 310 3 (2003) 889-896
91. Van Den Steen P.E., Wuyts A., Husson S.J., Proost P., Van Damme J., and Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 270 18 (2003) 3739-3749
92. Van Lint P., Wielockx B., Puimege L., Noel A., Lopez-Otin C., and Libert C. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J Immunol 175 11 (2005) 7642-7649
93. Vergote D., Butler G.S., Ooms M., Cox J.H., Silva C., Hollenberg M.D., et al. Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc Natl Acad Sci USA 103 50 (2006) 19182-19187
94. von Hundelshausen P., Petersen F., and Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 97 5 (2007) 704-713
95. Walz A., and Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 171 2 (1990) 449-454
96. Walz A., Dewald B., von Tscharner V., and Baggiolini M. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med 170 5 (1989) 1745-1750
97. Wittamer V., Bondue B., Guillabert A., Vassart G., Parmentier M., and Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol 175 1 (2005) 487-493
98. Wolf M., Clark-Lewis I., Buri C., Langen H., Lis M., and Mazzucchelli L. Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am J Pathol 162 4 (2003) 1183-1190
99. 2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur J Biochem 260 2 (1999) 421-429
100. Zabel B.A., Allen S.J., Kulig P., Allen J.A., Cichy J., Handel T.M., et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 280 41 (2005) 34661-34666
101. Zabel B.A., Zuniga L., Ohyama T., Allen S.J., Cichy J., Handel T.M., et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol 34 8 (2006) 1021-1032
102. Zaitseva M., Peden K., and Golding H. HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta 1614 1 (2003) 51-61
103. Zhang K., McQuibban G.A., Silva C., Butler G.S., Johnston J.B., Holden J., et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 6 10 (2003) 1064-1071
104. Zlotnik A., and Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 12 2 (2000) 121-127
105. Zlotnik A., Yoshie O., and Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7 12 (2006) 243